In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: April 2010

Executive Summary

April's leaders included a $165mm deal that gave Allergan rights to Serenity's late-stage Ser120 for nocturia. Medtronic offered $313mm to buy cardiac device company ATS Medical. Of the nearly $1bn in IPO money, 85% came from one company - Shenzhen Hepalink Pharma. Follow-on dollars on the device side were strong, with two companies bringing over $70mm, while both biopharma and device companies together raised $568mm in private financings.

You may also be interested in...



Start-Up Scanwell Adds Another Collaboration, Targets Home COVID-19 Testing With BD

Scanwell Health, a leader in smartphone-enabled home diagnostics tests, has announced a partnership with Beckton Dickson.  

Execs On The Move: Slew Of Directorships At Zimmer And 908 Devices

908 Devices, Zimmer Biomet and Ortho Clinical Diagnostics have all appointed new directors, Biolase promotes executive vice president to chief executive officer role, and more.

Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis

The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.

Topics

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel